Return to homepagePandemic Pact

Panoptes Pharma Ges.mbH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Austrian Research Promotion Agency (FFG)

  • Principal Investigator

    N/A

  • Research Location

    Austria

  • Lead Research Institution

    Panoptes Pharma Ges.mbH

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The cytokine storm is responsible for the life-threatening pneumonia in severe COVID-19 disease courses. In previous studies, the active ingredient PP-001 had a unique dual mechanism of action, namely a very broad antiviral spectrum of activity and anti-inflammatory properties due to the prevention of the release of cytokines. The effect of the active ingredient in people with COVID-19 is now being tested in a clinical study.